tbuckley/cabot-search huggingface dataset:
Increasing use of mastectomy with immediate reconstruction and contralateral prophylactic mastectomy in breast-conservation candidates: A 14-year report from a comprehensive cancer center.
Authors: A. E. Dragun, J. Pan, E. C. Riley, B. B. Kruse, M. R. Wilson, S. Rai, D. Jain
Journal: Journal of Clinical Oncology (2011)

1104 Background: First-line surgical options for early stage breast cancer include breast-conserving surgery (BCS) or mastectomy. We analyzed factors that influence the receipt of mastectomy and resultant trends over time. Methods: We analyzed the rates of mastectomy and BCS for 1,634 women who underwent up-front surgical treatment for AJCC stage 0, I or II breast cancer between 1995 and 2008 using data from the University of Louisville James Graham Brown Cancer Center Cancer Registry. We examined the trend of treatment over time and assessed the probability of receiving mastectomy using multivariate logistic regression. Results: Overall, 65.9% of women received BCS and 34.1% received mastectomy over a 14-year period (annual BCS rate range: 38.6-77.7%). The mastectomy rate substantially decreased from 43.5% in 1995 to 22.5% in 2004 (p=0.0007), but then increased to 51.7% in 2008 (p<0.0001). During the years between 2004-2008 (vs. 1995-2003), there was a significant increase in the rates of mastectomy performed in conjunction with immediate reconstruction (IR: 35.7% vs. 8.4%; p<0.0001) and/or contralateral prophylactic mastectomy (CPM: 22.9% vs. 3.3%; p<0.0001). Based on the multivariate analysis, the rate of receiving mastectomy was drastically higher for patients treated since 2004 (vs. prior to 2004), uninsured and government-insured (vs. privately insured) patients, patients with pT2 disease (vs. pTis or pT1), patients with pN1 disease (vs. pNX or pN0). Conclusions: In this longitudinal registry study, major independent determinants of mastectomy for early stage breast cancer include year of diagnosis, insurance status, and stage. Mastectomy rates declined until 2004, but have since increased in conjunction with IR and CPM. Additional study is needed to identify the reasons for and consequences of the reemergence of radical surgery for early stage breast cancer in the era of multidisciplinary care.
The Challenge of Diagnosing Fanconi Anemia in Patients with Bone Marrow Failure (BMF): A Study in 82 BMF Patients.
Authors: Fernando O. Pinto, Thierry Leblanc, Gwenaelle Le Roux, Jerome Larghero, Bruno Cassinat, Moema Santos, Benoit Brethon, Caroline Oudot, Odile Maarek, Gerard Socie, Andre Baruchel, Eliane Gluckman, Jean Soulier
Journal: Blood (2006)
Use of quantitative gene expression in primary and highest Gleason pattern cancers to identify genes associated with clinical recurrence after radical prostatectomy.
Authors: E. A. Klein, S. M. Falzarano, T. Maddala, C. Millward, W. F. Novotny, R. J. Pelham, C. Magi-Galluzzi
Journal: Journal of Clinical Oncology (2011)

39 Background: Prostate biopsy may not adequately sample small, secondary or tertiary Gleason pattern tumors which can drive clinical outcome. We conducted a study to determine whether tumor-derived gene expression profiling could identify a distinct underlying biology associated with clinical recurrence (cR) after radical prostatectomy (RP) across both the primary and highest Gleason pattern (GP) samples. Methods: All patients (pts) with clinical stage T1/T2 prostate cancer treated with RP at Cleveland Clinic from 1987 to 2004 were identified (n∼f2,600). A cohort sampling design was used to select 127 patients with cR and 374 patients without cR after RP. Each patient had two spatially distinct tumor specimens sampled that included the primary GP and the highest GP. Surgical GS and clinical data were centrally reviewed. RNA was extracted from 6 manually dissected 10 μ m fixed paraffin embedded tissue sections obtained from the RP tumor specimens and expression of 732 cancer-related and reference genes was quantified using RT-PCR. Clinical recurrence-free interval (cRFI) was analyzed using Cox PH regression. Results: Blocks from 441 patients were evaluable. Median F/U was 5.8 years. Pts were mostly Caucasian (83%), clinical stage T1 (66%), had baseline PSA &lt;10 ng/mL (82%), and had surgical GS ≤7 (87%). As expected, surgical GP, biopsy GP, path T- stage, clin T-stage, baseline PSA, and year of surgery (p&lt;0.05, unadj) were associated with cRFI. In the primary and highest GP specimens respectively, 295 and 297 genes were significantly associated (unadj. p&lt;0.05) with cRFI. 235 genes were associated with cRFI in both specimens, well in excess of the number expected by chance. In a multivariate model adjusted for AUA risk group and allowing a 10% false discovery rate, 289 genes remained significantly and strongly associated with cRFI. Conclusions: Gene expression analysis using quantitative RT-PCR identified a large number of genes, and underlying biology, that are strongly associated with clinical recurrence in both the primary and highest GP. This information can be used to develop a biopsy-based assay that distinguishes indolent versus aggressive disease. [Table: see text]
Adoptive Transfer of T Cell Receptor (TCR)-Gene Engineered Allogeneic T Cells: Competitive Downregulation of Alloreactive Endogenous TCRs Reduces the Risk of Graft Versus Host Disease and Preserves Strong Graft Versus Leukemia Effects After MHC-Mismatched Hematopoietic Stem Cell Transplantation (HCT).
Authors: Wolfgang Koestner, Martin Hapke, Christoph Klein, Karl Welte, Bruce R. Blazar, Martin G. Sauer
Journal: Blood (2009)
Abstract 19: The Role of the National Institutes of Health in Cardiovascular Disease Research in the United States
Authors: Radmila Lyubarova, Michael W Itagaki
Journal: Circulation (2006)

Objective : The National Institutes of Health (NIH) is the largest government sponsor of biomedical research in the United States. While NIH grant support of promising research is well publicized, little is known about its role in research that is actually published. We evaluated the prominence of NIH-sponsored research in the cardiovascular disease literature originating from the United States.

Methods : The Pubmed database of the National Library of Medicine was searched for articles published by U.S. institutions between 1996 and 2005 containing the keywords “cardiolog,” “cardiovascular,” and “cardiac,” in the author affiliation field. Acknowledgement of NIH grant support, study methodology and year of publication were noted. Trends were tested by using linear regression curve fitting.

Results: There were 32,592 articles identified from 1,631 unique journals. The NIH funded a sizeable fraction of all journal articles (27.94%), general research articles (38.05%), randomized, controlled trials (17.57%), and multicenter trials (11.26%). An increasing trend was noted for all journal articles (11.39% growth annually, P<0.0005), and for several study methodologies, including general research articles (7.09%, P=0.011), randomized, controlled trials (16.57%, P<0.0005), and multicenter studies (25.79%, P<0.0005). The National Heart, Lung, and Blood Institute (NHLBI) sponsored the most articles (67.28%) and had the greatest absolute growth rate (56.42 articles/year, 11.4 percent/year, P<0.0005). Other growing supporters included the National Center for Research Resources (10.52 articles/year, 27.69 percent/year, P<0.0005), the National Institute of Diabetes & Digestive & Kidney Diseases (7.79 articles/year, 39.97 percent/year, P<0.0005), and the National Institute on Aging (11.04 articles/year, 73.58 percent/year, P<0.0005).

Conclusions : The federal support for cardiovascular disease research in U.S. is increasing. The NIH plays a greater role in sponsoring general research than clinical trials. The NHLBI sponsors the most published cardiovascular research of all the NIH institutes and has the greatest absolute growth. On a percentage basis, sponsorship from the National Institute on Aging is increasing most rapidly.
Efficacy and Safety of Deferasirox (Exjade®) during 1 Year of Treatment in Transfusion-Dependent Patients with Myelodysplastic Syndromes: Results from EPIC Trial
Authors: Norbert Gattermann, Mathias Schmid, Matteo Della Porta, Kerry Taylor, John F Seymour, Dany Habr, Gabor Domokos, Abdel Hmissi, Agnès Guerci-Bresler, Christian Rose
Journal: Blood (2008)
Electrochemotherapy for large locoregional recurrence of breast cancer: Results from a phase II clinical trial showing efficacy in heavily pretreated patients.
Authors: L. W. Matthiessen, H. H. Johannesen, H. W. Hendel, T. Moss, C. Kamby, J. Gehl
Journal: Journal of Clinical Oncology (2011)

e11583 Background: Loco-regional recurrences of breast cancer may cause considerable discomfort due to ulceration, oozing, bleeding and pain. Electrochemotherapy (ECT) is a local treatment using electric pulses to permeabilize cell membranes, augmenting uptake of chemotherapy. For bleomycin, the effect is enhanced several hundred fold, enabling one or few treatments. ECT has proven efficient for small cutaneous tumours, but has not previously been systematically investigated for large cutaneous tumours. Methods: We conducted a phase II, non randomized trial for patients with loco-regional recurrences of breast cancer larger than 3 cm with no further standard treatment available. Primary endpoint was response evaluated with measurement of lesion extension. Secondary endpoints included response evaluated with PET/CT. All treatments were given in general anaesthesia with iv. injection of bleomycin (15000 IU/m2) followed by application of trains of 8 high-voltage pulses of 1 ms. Up to 4 treatments could be given. Results: Seventeen patients were included and treated with ECT, five were lost to follow up due to systemic PD, necessitating other antineoplastic treatment, 12 patients were evaluable with a follow up > 8 weeks. Patients were previously treated with chemotherapy (median 4 regimes pr. patient, range 1-7) and 16 of 17 patients had previous radiotherapy. A median of 1 treatment (range 1-4) were given and each treatment lasted 23 min (range 10-36 min). CR was observed in 1 patient and PR in 1 patient using clinical examination for response evaluation and the trial was terminated. PET/CT showed 4 out of 12 (33%) achieving over 50% tumour volume reduction. Five of 12 patients reported less exudate. Treatment was well tolerated with post-treatment pain being the main side-effect. No decrease in lung function (DLCO) was observed. Conclusions: In this heavily pre-treated patient population significant tumour reduction and symptomatic relief was obtained. Electrochemotherapy is an efficient, well tolerated, simple and inexpensive treatment alternative for loco-regional recurrences of breast cancer.
Patterns of reconstruction after unilateral and bilateral mastectomies.
Authors: K. M. Erb, T. B. Julian
Journal: Journal of Clinical Oncology (2011)

143 Background: A trend for the increased usage of mastectomy to treat breast cancer and for prophylaxis has been reported. Postmastectomy reconstruction (PMR) may improve body image and quality of life for breast cancer survivors. This prompted an investigation of the current pattern of PMR in our breast surgery practice. Methods: An IRB-approved retrospective chart review of women who had mastectomies performed by dedicated breast surgeons from 2006 through 2009 was completed. Data collected included age, unilateral (ULM) or bilateral mastectomy (BLM), type and timing of reconstruction, BRCA status, presence of an in-breast tumor recurrence (IBTR). Two-sided Fisher exact test and t-test were used in comparing groups. Results: From 2006 to 2009, 231 patients ranging in age from 27 to 91 years had ULM (n=155) or BLM (n=76). 38% of the patients had PMR. Patients &lt;50 years old were more likely to undergo PMR than those &gt;50 (67.5% versus 22.7%, p&lt; 0.0001). 4 patients &gt;70 years old had PMR. PMR followed ULM 27.7% of the time and BM 57.9% (p &lt; 0.0001). Only 6 patients underwent delayed PMR. 30 patients had mastectomies after IBTR with 36.7% having PMR and 36.7% opting for BLM. These rates were not significantly different from women with a unilateral de novo breast cancer (33.1% and 21.3%, respectively). In 15 patients with a BRCA mutation, one had ULM. The 14 having BLM were more likely to have BMR than BLM patients without a mutation (92.9% versus 50.0%, respectively, p=0.0029) and were younger (44.6 versus 52.3 years, respectively, p=0.0166). Types of reconstructions were divided between tissue expander/implant (TE/I)(70%) and autologous tissue flaps (AT) techniques. After BLM, TE/I was employed more frequently than after UM (84% versus 56%, respectively, p=0.005). From 2006 to 2009, there was no significant change in type or frequency of PMR. Conclusions: From this data it appears that a majority of women do not have PMR and few women return for a delayed PMR. Fewer women seek PMR after ULM. Rates and types of PMR have not changed over this time period. Further investigation to determine if women feel informed about PRM and to identify factors influencing their choices may be helpful in improving a PMR program.
Role of Growth Arrest-Specific Gene 6 Product (Gas6) in Severe Sepsis.
Authors: Laurent Burnier, Didier Le Roy, Thierry Roger, Thierry Fumeaux, François Saller, Marc Chanson, Delphine Borgel, Rocco Sugamele, Stéphanie Rignault, Peter Carmeliet, Jérôme Pugin, Marc Schapira, François Feihl, Thierry Calandra, Anne Angelillo-Scherrer
Journal: Blood (2006)
Compliance with consensus recommendations for systemic therapy, breast cancer intrinsic subtype, and clinical outcome.
Authors: S. Takayama, J. Matsui, N. Ando
Journal: Journal of Clinical Oncology (2011)

262 Background: Consensus recommendations for breast cancer are come into wide use, and we believe clinical guidelines leads our patients to improved outcome. Recently, gene profiling can be available, and immunohistochemical surrogates for molecular subtyping can provide much of prognostic and predictive factors. We investigated the relationship between compliance with consensus recommendations and clinical outcome of each subtype on the hypothesis that conformity with consensus recommendations is associated with increased survival among all intrinsic subtypes. Methods: We investigated breast cancer patients operated in our hospital from 2002 to 2004. DCIS, Stage 4 and male breast cancer were excluded. Patients were divided into luminal A (ER+ and/or PgR+, HER2-, low nuclear grade (NG)), luminal B (ER+ and/or PgR+, HER2-, high NG), luminal-HER2 (ER+ and/or PgR+, HER2+), HER2 (ER-, PgR-, HER2+) and triple negative (TN), (ER-, PgR-, HER2-). All patients were divided into compliance group or non-compliance group according to their conformity with consensus recommendations. Kaplan-Meier analysis was used in statistical studies. Results: 121 breast cancer patients were eligible and investigated in this study. Median follow-up period was 6.7 years. Fifteen relapse cases (12.4%) were identified. Among luminal A patients, compliance group was significantly associated with better recurrence free survival compared with non-compliance group with Kaplan-Meier analysis (p&lt;0.001). In contrast, there was no difference between compliance group and non-compliance group among the other subtypes. Median time to recurrence (4.2 year) in non-compliance group among luminal A was apparently longer than that (1.7 year) in compliance group among the other subtypes. Conclusions: Compliance group was significantly associated with better clinical outcome compared with non-compliance group among luminal A. This study suggests that cautious follow-up is required against non-compliance patients among luminal A, because time to recurrence of them was longer than that of both compliance and non-compliance subgroups among the other subtypes.
Clinical Diagnosis of Mental Disorders Before Cancer Diagnosis—Reply
Authors: Donghao Lu, Unnur Valdimarsdóttir, Fang Fang
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Fluorescence-activated cell sorting (FACS) and immunofluorescence (IF) detection and characterization of circulating tumor cells (CTC) from men with castrate-resistant prostate cancer (CRPC).
Authors: R. Z. Szmulewitz, A. J. Wyche, E. M. Posadas, W. M. Stadler
Journal: Journal of Clinical Oncology (2011)

41 Background: Men with progressive CRPC have identifiable CTC. The currently available technologies for isolation of these CTC are limited by requiring send out to a central lab, high cost, and relative inflexibility with regards to characterization of the CTC. We hypothesized that modern FACS techniques followed by IF could be utilized for point of care isolation and characterization of CTC from men with CRPC. Methods: Patients (pts) with progressive CRPC according to Prostate Cancer Working Group 2 criteria were eligible. 15mL of whole blood was collected in BD CPT Vacutainer tubes. The mononuclear cell layer was labeled with primary antibodies against CD45 and EpCAM conjugated to separate flours. The EpCAM+/CD45− population was sorted directly onto a chamber slide, fixed and stained for multiplex IF imaging of markers including: pan-cytokeratin (CK), PSA, and the androgen receptor (AR). Imaged cells were considered CTC if were nucleated and PSA or CK positive. The methodology would be considered feasible if ≥ 5 of the first 15 pts had detectable CTC. Results: 15 pts with progressive CRPC were accrued to the study. Of these, 14 had documented skeletal metastases and 13 had progressed through docetaxel chemotherapy. 13/15 pts had EpCAM+/CD45− events on flow cytometry; median 94 (range 0–1700). Ten patients had CTC imaged after IF staining. A median of 4 (0–25) CTC were detected, but in 7 pts with &gt;100 events by flow, all had detectable CTC with a median 22 (10–25) (p&lt;0.001 vs. # events &lt;100). A total of 9 contaminating cells (nucleus but no CK or PSA) were observed. All CTC stained positive for AR with variable intensity. Conclusions: FACS followed by IF is feasible for detection of CTC from men with metastatic CRPC. There is considerable loss of CTC during the processing, however, in men with &gt;100 EpCAM+ events, CTC can be imaged and characterized routinely with these methods. This is a promising technique for utilization in translational research given the relative flexibility, ease and cost. Patients are now being enrolled for pre-analytical validation of IF staining for multiple prostate cancer biomarkers including AR. No significant financial relationships to disclose.
Candidate biomarkers identified in the saliva of patients with pancreatic adenocarcinoma.
Authors: Jason B. Fleming, Cynthia Trajtenberg
Journal: Journal of Clinical Oncology (2012)

173 Background: There is currently no simple test to identify patients with pancreatic ductal adenocarcinoma (PDAC). The goal of this research is to develop such a method. We hypothesized that the salivary proteome of patients with localized PDAC contains a protein set distinct from normal subjects. Methods: We collected, processed and stored stimulated whole salivary gland secretions from patients with Stage I-II PDAC and aged-matched healthy volunteers. Fluorescently-labeled proteins were separated using 2D DIGE. Overlay imaging techniques compared 2D DIGE results, and spots representing individual proteins were quantified by signal, isolated from the gels, processed and protein identified using MALDI-TOF Mass Spectrometry. The SWISS-PROT database was used to identify proteins, and the ratio of signal in cancer versus normal samples was quantified and compared using Student’s t-test. Results: Samples from 10 PDAC patients and 10 healthy subjects were compared. A total of 96 spots on the 2D-DIGE comparison were uniquely present or absent in PDAC patient saliva. MALDI-TOF Mass Spectrometry examination of these 96 characterized 53 unique proteins. After eliminating duplicates and proteins without significant differences (p-value &lt;0.02), a total of 30 proteins were identified with levels higher (n=18) or lower (n=12) in saliva from PDAC patients versus normal subjects. Conclusions: Examination of saliva from pancreatic cancer patients identified a set of proteins unique from normal subjects. These proteins represent targets for the development of biomarkers that could be used in early detection of pancreatic cancer.
Comparison of Three Prognostic Scoring Systems in a Series of 146 Cases of Chronic Myelomonocytic Leukemia (CMML): MD Anderson Prognostic Score (MDAPS), CMML-Specific Prognostic Scoring System (CPSS) and Mayo Prognostic Model
Authors: Xavier Calvo, Meritxell Nomdedeu, Rodrigo Santacruz, Núria Martínez, Dolors Costa, Arturo Pereira, Natalia Estrada, Blanca Xicoy, Jordi Esteve, Benet Nomdedeu
Journal: Blood (2014)
Correction of Wiskott-Aldrich Syndrome by Hematopoietic Stem Cell Gene Therapy
Authors: Kaan Boztug, Manfred Schmidt, Adrian Schwarzer, Pinaki Banerjee, Marie Böhm, Rita Beier, Inés Avedillo Díez, Ricardo Dewey, Claudia R Ball, Ali Nowrouzi, Sonja Naundorf, Klaus Küuhlcke, Rainer Blasczyk, Martina Rose, Christopher Fraser, Mathias Liesl, Rudolf Ferrari, Miguel R. Abboud, Waleed Al-Herz, Irina Kondratenko, László Maródi, Jordan Orange, von Kalle Christof, Christoph Klein
Journal: Blood (2010)
Diagnostic Significance of Haptoglobin Concentration in Patients with Bone Marrow Failure Syndromes.
Authors: Kazuhiko Ikeda, Naoto Takahashi, Junichi Kameoka, Katsushi Tajima, Akiko Nakamura, Sayuri Mizuno, Takeshi Sasaki, Ken-Ichi Sawada, Yukio Maruyama, Tsutomu Shichishima
Journal: Blood (2006)
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
Authors: J R Jones, D A Cairns, W M Gregory, C Collett, C Pawlyn, R Sigsworth, A Striha, R Henderson, M F Kaiser, M Jenner, G Cook, N H Russell, C Williams, G Pratt, B Kishore, J Lindsay, M T Drayson, F E Davies, K D Boyd, R G Owen, G H Jackson, G J Morgan
Journal: Blood Cancer Journal (2016)

Abstract We have carried out the largest randomised trial to date of newly diagnosed myeloma patients, in which lenalidomide has been used as an induction and maintenance treatment option and here report its impact on second primary malignancy (SPM) incidence and pathology. After review, 104 SPMs were confirmed in 96 of 2732 trial patients. The cumulative incidence of SPM was 0.7% (95% confidence interval (CI) 0.4–1.0%), 2.3% (95% CI 1.6–2.7%) and 3.8% (95% CI 2.9–4.6%) at 1, 2 and 3 years, respectively. Patients receiving maintenance lenalidomide had a significantly higher SPM incidence overall ( P =0.011). Age is a risk factor with the highest SPM incidence observed in transplant non-eligible patients aged &gt;74 years receiving lenalidomide maintenance. The 3-year cumulative incidence in this group was 17.3% (95% CI 8.2–26.4%), compared with 6.5% (95% CI 0.2–12.9%) in observation only patients ( P =0.049). There was a low overall incidence of haematological SPM (0.5%). The higher SPM incidence in patients receiving lenalidomide maintenance therapy, especially in advanced age, warrants ongoing monitoring although the benefit on survival is likely to outweigh risk.